Search

Your search keyword '"Muggia, Franco"' showing total 1,332 results
Start Over Author "Muggia, Franco"
1,332 results on '"Muggia, Franco"'

2. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Author

Rose, Peter G, Java, James J, Salani, Ritu, Geller, Melissa A, Secord, Angeles Alvarez, Tewari, Krishnansu S, Bender, David P, Mutch, David G, Friedlander, Michael L, Van Le, Linda, Method, Michael W, Hamilton, Chad A, Lee, Roger B, Wenham, Robert M, Guntupalli, Saketh R, Markman, Maurie, Muggia, Franco M, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, and Copeland, Larry J

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Ovarian Cancer, Clinical Research, Rare Diseases, Aged, Antineoplastic Agents, Phytogenic, Carcinoma, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Nomograms, Ovarian Neoplasms, Paclitaxel, Platinum Compounds, Retrospective Studies, United States, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine, Reproductive medicine
Abstract

ObjectiveTo analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma and to develop a nomogram to predict individual survival after recurrence.MethodsWe retrospectively analyzed patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian-peritoneal-tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and subsequently developed recurrence. Prognostic factors affecting survival were identified and used to develop a nomogram, which was both internally and externally validated.ResultsThere were 4,739 patients included in this analysis, of whom, 84% had stage III and 16% had stage IV ovarian carcinoma. At a median follow-up of 88.8 months (95% CI 86.2-92.0 months), the vast majority of patients (89.4%) had died. The median survival after recurrence was 21.4 months (95% CI 20.5-21.9 months). Time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age were significant variables used to develop a nomogram for survival after recurrence, which had a concordance index of 0.67. The time to recurrence alone accounted for 85% of the prognostic information. Similar results were found for patients who underwent second look laparotomy and had a complete pathologic response or received intraperitoneal chemotherapy.ConclusionFor individuals with advanced-stage ovarian carcinoma who recur after standard first-line therapy, estimated survivals after recurrence are closely related to the time to recurrence after chemotherapy and prognostic variables can be used to predict subsequent survival.Clinical trial registrationClinialTrials.gov, NCT00002568, NCT00837993, NCT00002717, NCT01074398, and NCT00011986.

Published
2019

4. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

Author

Oliver, Kate E, Brady, William E, Birrer, Michael, Gershenson, David M, Fleming, Gini, Copeland, Larry J, Tewari, Krishnansu, Argenta, Peter A, Mannel, Robert S, Secord, Angeles Alvarez, Stephan, Jean-Marie, Mutch, David G, Stehman, Frederick B, Muggia, Franco M, Rose, Peter G, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, and Farley, John H

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Ovarian Cancer, Rare Diseases, Adenocarcinoma, Clear Cell, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cystadenocarcinoma, Serous, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Survival Rate, Clear cell, Histology, Ovarian, Survival, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

PurposeWe examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC).MethodsWe reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous).ResultsThere were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I-II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p

Published
2017

7. Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery

Author

Muggia, Franco M, Bonetti, Andrea, Hoeschele, James D, Rozencweig, Marcel, and Howell, Stephen B

Subjects
Antineoplastic Agents, Carboplatin, Cisplatin, Drug Resistance, Neoplasm, Faculty, Medical, History, 20th Century, History, 21st Century, Humans, Kidney, Nervous System, Organoplatinum Compounds, Oxaliplatin, Platinum Compounds, United States, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Published
2015

16. Challenges posed by non‐random missing quality of life data in an advanced‐stage colorectal cancer clinical trial

Author

Moinpour, Carol M, Triplett, Julia Sawyers, McKnight, Barbara, Lovato, Laura C, Upchurch, Christine, Leichman, Cynthia G, Muggia, Franco M, Tanaka, Leora, James, Wendy A, Lennard, Martha, and Meyskens, Frank L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Behavioral and Social Science, Colo-Rectal Cancer, Clinical Research, Clinical Trials and Supportive Activities, Digestive Diseases, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Bias, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Colorectal Neoplasms, Cross-Sectional Studies, Data Collection, Data Interpretation, Statistical, Female, Fluorouracil, Humans, Longitudinal Studies, Male, Middle Aged, Neoplasm Staging, Quality of Life, Randomized Controlled Trials as Topic, Reproducibility of Results, Research Design, Surveys and Questionnaires, Oncology and Carcinogenesis, Psychology, Oncology & Carcinogenesis, Biomedical and clinical sciences
Abstract

Effects of variations in agent, dose, and route of treatment administration on patient reported quality of life (QOL) were examined for 279 patients enrolled on a seven-arm randomized clinical trial (S8905) of 5-FU and its modulation for advanced colorectal cancer. Patients completed QOL questionnaires at randomization and weeks 6, 11, and 21 post-randomization with five QOL endpoints considered primary: three treatment-specific symptoms (stomatitis, diarrhea, and hand/foot sensitivity); physical functioning; and emotional functioning. Patient compliance with the QOL assessment schedule was good, supporting the feasibility of including QOL measures in cooperative group trials. However, death and deteriorating health produced substantial missing data. Cross-sectional analyses indicated that the seven therapeutic arms did not differ in their impact on QOL. Unfortunately, longitudinal analyses of the QOL data were inappropriate given non-random missing data. Graphical presentation of non-random missing data identified the seriousness of this problem and its effect on potential conclusions about QOL during treatment. This problem appears to be particularly challenging in the context of advanced-stage disease. Failure to recognize the presence of non-random missing data can lead to serious overestimates of patient QOL over time.

Published
2000

21. Platinum Compounds and Radiation

Author

Baer, Lea, Muggia, Franco M., Formenti, Silvia C., Bonetti, Andrea, editor, Leone, Roberto, editor, Muggia, Franco M., editor, and Howell, Stephen B., editor

Published
2009
Full Text
View/download PDF

26. Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points

Author

Boyd, Leslie R. and Muggia, Franco M.

Subjects
Ovarian cancer -- Development and progression -- Drug therapy, Carboplatin -- Patient outcomes, Paclitaxel -- Patient outcomes, Chemotherapy -- Methods -- Patient outcomes, Toxicity, Activities of daily living, Waste management, Comorbidity, Thrombocytopenia, Clinical trials, Alopecia, Health
Abstract

The carboplatin/paclitaxel doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with carboplatin dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/paclitaxel. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with paclitaxel, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of paclitaxel, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the carboplatin/paclitaxel doublet; preventive measures must be considered for patients who would otherwise refuse treatment. Several first-line phase III trials, as well as ongoing trials for which only preliminary results have been published, have fueled debates on the optimal dose and schedule; these have focused not only on weekly vs q3-weeks paclitaxel, but also on other modifications and the advisability of adding bevacizumab. Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by carboplatin, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying paclitaxel dose and schedule and the addition of bevacizumab are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available., IntroductionThe regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment: 95% of women diagnosed with ovarian cancer will receive this regimen. It has been 15 years [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results